TanyaSiddiqiMD

Hematology • Irvine, CA

Clotting Disorder, Hematologic Oncology

Medical Director of Lymphoma, COH-OC and Director, CLL Program

Join to view full profile

Dr. Siddiqi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Siddiqi's full profile

Already have an account?

Office
1000 FivePoint
Irvine, CA 92618
Phone+1 949-999-8979

Fax+1 626-389-3061

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Aga Khan Medical CollegeClass of 2000
University of ConnecticutResidency, Internal Medicine

Certifications & Licensure

CA State Medical License 2009 - 2025
MA State Medical License 2006 - 2011
American Board of Internal Medicine Hematology

Clinical Trials

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Start of enrollment: 2012 Apr 16
Completed
Phase 1
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Start of enrollment: 2014 Sep 24
Active, not recruiting
Phase 1
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation Start of enrollment: 2023 Jun 02
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma Start of enrollment: 2023 Jun 29
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers.
Arnon P Kater, Tanya Siddiqi
Hematology. American Society of Hematology. Education Program. 2024-12-06
1 citations
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy.
Jennifer S Woo, Kim Nguyen, Lawrence Liu, Amrita Krishnan, Tanya Siddiqi
Seminars in Hematology. 2024-10-01
deletion leads to Richter's transformation by modulating mitochondrial OXPHOS.
Prajish Iyer, Bo Zhang, Tingting Liu, Meiling Jin, Kevyn Hart
Science Translational Medicine. 2024-07-31

Abstracts/Posters

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...
Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lympho...
Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Tanya Siddiqi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patient...
2019 ASCO Annual Meeting - 6/1/2019
Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

Contraception for women with inherited thrombophilias
Siddiqi T, Bauer KA, Barbieri RL
http://www.uptodate.com/contents/contraception-for-women-with-inherited-thrombophilias
UpToDate, Wolters Kluwer Health - 2013-04-01

Press Mentions

Survival Similar in CLL Without Undetectable MRD Regardless of Continued Therapy TypeApril 26th, 2023
City of Hope Scientists Present Potential New Treatments for Chronic Lymphocytic Leukemia, Myelofibrosis and Other Diseases at American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023
YOUR HEALTH: CAR T Cells Save Chuck from Non-Hodgkin LymphomaFebruary 28th, 2023
Join now to see all